Результаты поиска - David D. Stenehjem

  • Отображение 1 - 8 результаты of 8
Отмена результатов
  1. 1
    Panobinostat for the treatment of multiple myeloma: the evidence to date

    Panobinostat for the treatment of multiple myeloma: the evidence to date по Sunil Sharma, Hanna Bailey, David D. Stenehjem

    Опубликовано 2015
    Полный текст Полный текст
    Revisão
    Добавить в Избранное
    Сохранить в:
  2. 2
    PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer

    PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer по David D. Stenehjem, Dao Tran, Michael Nkrumah, Shilpa Gupta

    Опубликовано 2018
    Полный текст Полный текст
    Revisão
    Добавить в Избранное
    Сохранить в:
  3. 3
    Tumor mutational burden in lung cancer: a systematic literature review

    Tumor mutational burden in lung cancer: a systematic literature review по Connor Willis, Michelle Fiander, Dao Tran, Beata Korytowsky, John-Michael Thomas, Florencio Calderon, Teresa Zyczynski, Diana Brixner, David D. Stenehjem

    Опубликовано 2019
    Полный текст Полный текст
    Revisão
    Добавить в Избранное
    Сохранить в:
  4. 4
    Cancer incidence in immunocompromised patients: a single-center cohort study

    Cancer incidence in immunocompromised patients: a single-center cohort study по Sabrina Ilham, Connor Willis, Kibum Kim, Karen Chung, Brenda Wood, Malinda S. Tan, Chia Jie Tan, Danielle Nguyen, Diana Brixner, David D. Stenehjem

    Опубликовано 2023
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  5. 5
    Real-world outcomes of immunotherapy–based regimens in first-line advanced non-small cell lung cancer

    Real-world outcomes of immunotherapy–based regimens in first-line advanced non-small cell lung cancer по David Waterhouse, Jenny Lam, Keith A. Betts, Lei Yin, Sophie Gao, Yong Yuan, John Hartman, Sumati Rao, Solomon J. Lubinga, David D. Stenehjem

    Опубликовано 2021
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  6. 6
    Neutrophil-lymphocyte ratio as a predictive biomarker for response to high dose interleukin-2 in patients with renal cell carcinoma

    Neutrophil-lymphocyte ratio as a predictive biomarker for response to high dose interleukin-2 in patients with renal cell carcinoma по James A. Kuzman, David D. Stenehjem, Joseph A. Merriman, Archana M. Agarwal, Shiven B. Patel, Andrew W. Hahn, Anitha Alex, Dan Albertson, David Gill, Neeraj Agarwal

    Опубликовано 2017
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  7. 7
    Circulating immune cell phenotype dynamics reflect the strength of tumor–immune cell interactions in patients during immunotherapy

    Circulating immune cell phenotype dynamics reflect the strength of tumor–immune cell interactions in patients during immunotherapy по Jason I. Griffiths, Pierre Wallet, Lance Pflieger, David D. Stenehjem, Xuan Liu, Patrick A. Cosgrove, Neena A. Leggett, Jasmine A. McQuerry, Gajendra Shrestha, Maura Rossetti, Gemalene Sunga, Philip J. Moos, Frederick R. Adler, Jeffrey T. Chang, Sunil Sharma, Andrea H. Bild

    Опубликовано 2020
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  8. 8
    American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer

    American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer по Gary H. Lyman, Marc Carrier, Cihan Ay, Marcello Di Nisio, Lisa K. Hicks, Alok A. Khorana, Andrew D. Leavitt, Agnes Y.Y. Lee, Fergus Macbeth, Rebecca L. Morgan, Simon Noble, Elizabeth A. Sexton, David D. Stenehjem, Wojtek Wiercioch, Lara A Kahale, Pablo Alonso‐Coello

    Опубликовано 2021
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:

Инструменты поиска: